Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn's disease: results from a multicentre cohort study.
Bacsur P, Matuz M, Resál T, Miheller P, Szamosi T, Schäfer E, Sarlós P, Iliás Á, Szántó K, Rutka M, Bálint A, Milassin Á, Fábián A, Bor R, Szepes Z, Molnár T, Farkas K. Bacsur P, et al. Among authors: ilias a. Therap Adv Gastroenterol. 2022 Dec 26;15:17562848221144349. doi: 10.1177/17562848221144349. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 36600684 Free PMC article.
Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.
Gonczi L, Szanto K, Farkas K, Molnar T, Szamosi T, Schafer E, Golovics PA, Barkai L, Lontai L, Lovasz B, Juhasz M, Patai A, Sarang K, Vincze A, Sarlos P, Farkas A, Dubravcsik Z, Toth TG, Miheller P, Ilias A, Lakatos PL. Gonczi L, et al. Among authors: ilias a. Dig Liver Dis. 2022 Feb;54(2):207-213. doi: 10.1016/j.dld.2021.07.008. Epub 2021 Jul 31. Dig Liver Dis. 2022. PMID: 34344576
Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study.
Lontai L, Gonczi L, Balogh F, Komlodi N, Resal T, Farkas K, Molnar T, Miheller P, Golovics PA, Schafer E, Szamosi T, Ilias A, Lakatos PL. Lontai L, et al. Among authors: ilias a. Dig Liver Dis. 2022 Dec;54(12):1639-1645. doi: 10.1016/j.dld.2022.07.004. Epub 2022 Aug 2. Dig Liver Dis. 2022. PMID: 35931624
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years.
Barkai LJ, Gonczi L, Balogh F, Angyal D, Farkas K, Farkas B, Molnar T, Szamosi T, Schafer E, Golovics PA, Juhasz M, Patai A, Vincze A, Sarlos P, Farkas A, Dubravcsik Z, Toth TG, Szekely H, Miheller P, Lakatos PL, Ilias A. Barkai LJ, et al. Among authors: ilias a. Sci Rep. 2024 Jun 28;14(1):14909. doi: 10.1038/s41598-024-65987-1. Sci Rep. 2024. PMID: 38942890 Free PMC article.
92 results